Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mF1v2jAUhu/5FVHuSaBQClOg2li7IbUqo6BNu6lMcgCz1E6PbT726+cQ0OjkqKvBl7Gd95z4vH58lOh685x6K0BBOev69aDme8BinlA27/qT8W217V/3KtGSrMjRsqugFtQvfC9OiRBdP58NpkCYCH7c330G/T6g36t4EZ8uIZav1ilJ0+ArEYt7kuVrvGjFaeI9g1zwpOtnSu5GvUhI1Fn01hx/iYzEEIX7kePZ5VPzeDwKc7H/UFUC8I6wuVEUmJVmrBCByT6RMOe4Lcm3YaVNxQgEVxjDkMjFEPmKJpAYQ8xIKsAqyGydPAKuUpB5EKN4uIyfhZU4WZLNCF4G5qQ/6tm+3MhqrVq/anYatWarWWu02lah8GirzFXQHxHGT+1W66pzEQILSaxdubXcNiqGHCVJHVWFiv5rYzmKg/DyZvUTKrKUbIOlyGy3iiDR04D6+Lv7kPwLxqiBlOo9+0efqTQN35n1ZI8LRxnnNOpzxWQJNW5HthvR50zCpryidqCTm70XKYjzyf7mzAz5oZqmNLZFmoaOAiEno0E50c4Jg09EwATd0eA7ZQlfi/NT5riqjrLPdqA0imaY1J8uOu1W/fLS+hD91BYquWFuFPIMQs0fKk7ByoDN+KlA0a40Sx08eTY77vocHpMUSjqdqiVbtA8PjZkzp7s7RcWEUfTLzdjWHt8U4PZx92iUpkn3UFg77rqAufZiad7vd3ZxwJ20wArN4FhImYkPYbher4MFEVVB9C4FMzw72I/uUncNuJMLu2hgCjg6Sn1a3Hrvq5DtQXvrSj+1Td2/v2+HjTEkKjihFgWTnZFzcHN+GP/tUZ2lPXxFD3dhdv0kkZQzV32OmhoVT8K/Liu7Rc2Hh9mMlvwPKbVlFBb/YnqVKMz/w/QqfwAkzeWJ
TuSD8KutCkM5w72Z
Listen
